You are here

  • Home
  • Archive
  • Volume 34, Issue Suppl 1
  • 1052 KORE INNOVATION: the first prospective clinical trial to assess a perioperative procedure to reduce postoperative complications in ovarian cancer patients – first experiences about adherence to preoperative carbohydrate loading

Article Text

Article menu
Download PDFPDF
Poster and E-Posters
06. Ovarian cancer
1052 KORE INNOVATION: the first prospective clinical trial to assess a perioperative procedure to reduce postoperative complications in ovarian cancer patients – first experiences about adherence to preoperative carbohydrate loading
  1. Marlene Lee1,
  2. Eva Schnura2,
  3. Jalid Sehouli1,
  4. Julia Klews3,
  5. Philipp Harter2,
  6. Radoslav Chekerov1,
  7. Melisa Gülhan Inci1,
  8. Manuela Zimmermann3,
  9. Phil Nigemann4,
  10. Stephanie Roll5,
  11. Thomas Reinhold5,
  12. Stephan N Willich5,
  13. Max Emanuel Liebl5,
  14. Adak Pirmorady-Sehouli6,
  15. Engi Algharably7,
  16. Chiara Flethe1,
  17. Helena Lindemann1,
  18. Florian Heitz1,
  19. Malak Moubarak8 and
  20. Stephanie Rosenbaum8
  1. 1Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Gynecology with Center for Oncological Surgery, Augustenburger Platz 1, 13353 Berlin, Germany, Berlin, Germany
  2. 2Evangelische Kliniken Essen Mitte, Department of Gynecology and Gynecological Oncology, Henricistraße 92, 45136 Essen, Germany, Essen, Germany
  3. 3Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Nursing Science, Charitéplatz 1, 10117 Berlin, Germany, Berlin, Germany
  4. 4Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Anesthesiology, Augustenburger Platz 1, 13353 Berlin, Germany, Berlin, Germany
  5. 5Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Institute for Social Medicine, Epidemiology and Health Economics, Charitéplatz 1, 10117 Berlin, Germany, Berlin, Germany
  6. 6Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Psychosomatic Medicine, Hindenburgdamm 30, 12203 Berlin, Germany, Berlin, Germany
  7. 7Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Institute for Clinical Pharmacology and Toxicology, Charitéplatz 1, 10117 Berlin, Germany, Berlin, Germany
  8. 8Evangelische Kliniken Essen Mitte, Department of Gynecology and Gynecological Oncology, Henricistraße 92, 45136 Essen, Germany, Berlin, Germany

Abstract

Introduction/Background The implementation of perioperative care pathways such as the Enhanced Recovery After Surgery (ERAS) program can improve the quality of healthcare in complex operations such as the multivisceral surgery for patients with ovarian cancer. Adherence to individual ERAS-items is essential for effective treatment. One ERAS-item is the preoperative carbohydrate intake (CHO), which is associated with the reduction of postoperative insulin resistance and improved clinical outcomes.

Methodology The KORE INNOVATION is an ongoing clinical trial to assess the effects of an innovative multimodal perioperative care pathway consisting of prehabilitation combined with an ERAS-pathway to reduce complications for patients undergoing surgery for ovarian cancer. Preoperative carbohydrate loading (CHO) is given to the patients using a complex carbohydrate drink (CCD). Patients receive two bottles of CDD the evening before and one bottle of CDD two hours prior to surgery and are instructed by a specialized KORE nurse to self-administer the bottles.

Results 378 patients were included in the preliminary, descriptive analyses. 191 patients (50.5%) consumed the full dose of CHO (3 bottles CDD), while 258 (68.3%) patients consumed at least one bottle. 67.7% of patients consumed CHO in the evening before the operation and 58.5% in the morning of the operation. Pre-existing diabetes was a contraindication and was present in 5.8%. Reasons for not consuming CHO were: not received from staff (4.8%), refusal by patient (0.5% in the evening, 1.6% in the morning), poor taste of CDD (1.9% in the evening, 4% in the morning).

Conclusion The main reason for non-adherence to the CHO rejection of the CDD due to the poor taste according to the patients. Through patient empowerment by education and self-monitored ingestion, logistical factors (e.g. CDD not received) could be avoided and adherence could be increased.

Disclosures KORE INNOVATION is funded by the Innovationsfinds des Gemeinsamen Bundesausschuss (GBA), 01NVF18021.

https://doi.org/10.1136/ijgc-2024-ESGO.771

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.